Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Durie, Brian G., Rosiñol, Laura, Mateos, Maria-Victoria, Dispenzieri, Angela, Moreau, Philippe, Kumar, Shaji, Raje, Noopur, Munshi, Nikhil, Laubach, Jacob P., O’Gorman, Peter, O’Donnell, Elizabeth, Voorhees, Peter, Facon, Thierry, Bladé, Joan, Lonial, Sagar, Perrot, Aurore, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/
https://www.ncbi.nlm.nih.gov/pubmed/37608773
http://dx.doi.org/10.3324/haematol.2022.282624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/
https://www.ncbi.nlm.nih.gov/pubmed/37608773
http://dx.doi.org/10.3324/haematol.2022.282624

Ejemplares similares